Skip to content
Open access

Hypermethylation in CpG-rich cfDNA fragments enables accurate detection of circulating tumor DNA in BRCA1- and BRCA2-associated breast and ovarian cancer

Nov 2026 · npj Breast Cancer · Vol 12 · 0 citations · 56 references
Medicine

TL;DR

A targeted ultra-deep NGS assay for detecting tumor-derived ctDNA based on fragment-level hypermethylation of CpG-rich cfDNA is developed and enables highly specific, non-invasive hypermethylated ctDNA detection in HBOC populations.

Abstract

Pathogenic BRCA1 and BRCA2 germline variants confer an increased risk of hereditary breast and ovarian cancer (HBOC). In this high-risk cohort, novel biomarkers are needed to support patient management. While circulating cell-free DNA-based conventional CpG-level averaging is promising, it dilutes tumor-specific signals in samples with low circulating tumor DNA (ctDNA) fractions. Here, we developed a targeted ultra-deep NGS assay for detecting tumor-derived ctDNA based on fragment-level hypermethylation of CpG-rich cfDNA. A panel of 360 cancer-specific CpG-rich regions derived from 450k methylation array datasets from TCGA breast cancer and GEO ovarian cancer, was applied to plasma from 31 breast cancer, 16 ovarian cancer patients, and 26 healthy controls using enzymatic methylation sequencing. Hypermethylated ctDNA (hm-ctDNA) fragments, were significantly enriched in cancer cases, identifying 62.5% of ovarian and 38.7% of breast cancers at 100% specificity. Elevated hm-ctDNA was observed across different tumor stages, with higher burden in BRCA1-associated cases. This approach enables highly specific, non-invasive hypermethylated ctDNA detection in HBOC populations.

Read PDF

Similar papers

2025

Circulating Tumor DNA Methylation Signatures for Early-Stage Colorectal Cancer Detection and Tissue-of-Origin Classification: Validation in a Prospective 2,840-Patient Cohort

Findings contribute empirically to oncology and liquid biopsy diagnostics and carry actionable implications for the design of programs and policies targeting average-risk CRC screening adjunct to colonoscopy, post-polypectomy surveillance, and multi-cancer early detection panel development.

Thomas M. Eriksson, Adaeze N. Okafor, Mei-Lin T. Chen · 0 citations
Open access Oct 2026

Genome-Wide DNA methylation profiling of tissue-plasma pairs identifies Novel cfDNA biomarkers for the diagnosis of gastric cancer

Screening for gastric cancer (GC) is critical for improving patient survival, yet current clinical methods suffer from invasiveness and limited sensitivity. The aim of this study is to develop a machine learning model for the non-invasive diagnosis of GC using the whole-genome methylation profile of circulating free DN...

H. Ou, J. Miao, Fu-Sheng Ling et al. · 0 citations
Open access Oct 2026

SLC12A4 promoter methylation in plasma cell-free DNA as a candidate biomarker for thyroid cancer

Background Plasma cell-free DNA (cfDNA) methylation has emerged as a promising non-invasive approach for cancer detection; however, methylation biomarkers for thyroid carcinoma (THCA) remain insufficiently defined. This study aimed to identify THCA-associated DNA methylation alterations and evaluate their potential dia...

Wei Wu, Ye Wang, Ying Qu et al. · 0 citations
Open access Oct 2026

Whole-genome sequencing-based tumor-informed circulating tumor DNA monitoring for early detection of recurrence in patients with solid tumors

Abstract Background Circulating tumor DNA (ctDNA) assays can transform patient management by enabling molecular residual disease (MRD) detection, prognosis prediction, and treatment monitoring. Here, we report clinical performance of Signatera Genome, a whole-genome sequencing (WGS)-based ctDNA assay, in a diverse pan-...

Mridula A. George, G. Schwartz, W. McHayleh et al. · 0 citations
Oct 2026

Cell-free DNA methylation profiling for lung cancer risk stratification in an LDCT-based clinical cohort

Abstract Objectives Low-dose computed tomography (LDCT) screening enables earlier lung cancer detection but identifies indeterminate pulmonary findings in approximately 10–20 % of screened individuals. This study aimed to identify circulating cell-free DNA (cfDNA) methylation markers associated with lung cancer in an L...

Tereza Senkyrova, Petra Sauer Mikyskova, Anezka Kramarova et al. · 0 citations
Open access Oct 2026

Epigenome-Wide DNA Methylation Profiling of Matched Primary Breast Cancers and Brain Metastases Reveals Epigenetic Markers linked to Metastatic Progression: A Preliminary Study

Introduction Breast cancer represents the most prevalent malignancy among women globally, with a rising incidence of metastases to the central nervous system. The presence of brain metastases is associated with a poor prognosis, largely due to the limited availability of effective treatment modalities. Methods In this...

B. Alinger-Scharinger, G. Hutarew, Christoph Schwartz et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.